Blood pressure variability over 24 h: Prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination

Hypertension Research

Volumn 37, Issue 3, 2014, Pages 187-193

  Parati, Gianfranco ^a   Schumacher, Helmut ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

24 h ambulatory BP monitoring; amlodipine; BP variability; smoothness index; telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; LONG ACTING DRUG; TELMISARTAN;

AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HOME MONITORING; HUMAN; HYPERTENSION; MONOTHERAPY; OUTCOMES RESEARCH; PROGNOSIS; REVIEW; RISK REDUCTION; SMOOTHNESS INDEX; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PROGNOSIS; TREATMENT OUTCOME;

EID: 84895787929     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.145     Document Type: Review

References (94)

1. National Institute for Health and Clinical Excellence. Hypertension: Clinical management of primary hypertension in adults. NICE clinical guidance webpages. Last updated August 2011. http://guidance nice org uk/CG127.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
3. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van ZP, Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
4. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep 2006; 8: 199-204.
5. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Bjorklund-Bodegard K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Wang J, Ibsen H, O'Brien E, Staessen JA. Prognostic value of reading-to-reading blood pressure variability over 24 h in 8938 subjects from 11 populations. Hypertension 2010; 55: 1049-1057.
6. Hermida RC, Ayala DE, Fernandez JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens 2011; 24: 383-391.
7. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-210.
8. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 1: 795-797.
9. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011; 8: 686-693.
10. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, O'Brien E, Ohkubo T, Padfield P, Palatini P, Pickering T, Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waeber B, Zanchetti A, Mancia G. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26: 1505-1526.
11. Kim SK, Bae JH, Nah DY, Lee DW, Hwang TY, Lee KS. Frequency and related factors of masked hypertension at a worksite in Korea. J Prev Med Public Health 2011; 44: 131-139.
12. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001; 104: 1385-1392.
13. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46: 508-515.
14. Goldsmith D, Cork A. Blood pressure variability measurements. Nephrol Dial Transplant 2000; 15: 131-132.
15. Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol 2000; 35: S15-S19.
16. Modesti PA, Morabito M, Bertolozzi I, Massetti L, Panci G, Lumachi C, Giglio A, Bilo G, Caldara G, Lonati L, Orlandini S, Maracchi G, Mancia G, Gensini GF, Parati G. Weather-related changes in 24-hour blood pressure profile: effects of age and implications for hypertension management. Hypertension 2006; 47: 155-161.
17. Cuffe RL, Howard SC, Algra A, Warlow CP, Rothwell PM. Medium-term variability of blood pressure and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke. Stroke 2006; 37: 2776-2783.
18. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539-546.
19. Parati G, Valentini M. Prognostic relevance of blood pressure variability. Hypertension 2006; 47: 137-138.
20. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008; 2: 119-124.
21. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983; 2: 695-698.
22. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22: 435-445.
23. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De CR, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
24. White WB. Ambulatory blood pressure as a predictor of target organ disease and outcome in the hypertensive patient. Blood Press Monit 1999; 4: 181-184.
25. McGrath BP. Ambulatory blood pressure monitoring. Med J Aust 2002; 176: 588-592.
26. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415.
27. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den HE, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161.
28. Burr ML, Dolan E, O'Brien EW, O'Brien ET, McCormack P. The value of ambulatory blood pressure in older adults: the Dublin outcome study. Age Ageing 2008; 37: 201-206.
29. ARTEMIS Project Website. www artemisnet org 2012.
30. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133-1137.
31. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension 2012; 59: 212-218.
32. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102: 1536-1541.
33. Gosse P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc Health Risk Manag 2006; 2: 195-201.
34. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, Ambrosio G, Reboldi G. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012; 60: 34-42.
35. Iqbal P, Stevenson L. Cardiovascular outcomes in patients with normal and abnormal 24-hour ambulatory blood pressure monitoring. Int J Hypertens 2010; 2011: 786912.
36. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003; 42 (Suppl 1), S87-S91.
37. Redon J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the Control of Blood Pressure using Ambulatory Blood Pressure Monitoring. Blood Press Monit 2002; 7: 111-116.
38. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
39. Redon J, Bilo G, Parati GSURGE Steering Committee. Home blood pressure control is low during the critical morning hours in patients with hypertension: the SURGE observational study. Fam Pract 2011; 29: 421-426.
40. Williams B, Lacourciere Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs. ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23: 610-619.
41. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20: 2183-2189.
42. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006; 47: 149-154.
43. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57: 3-10.
44. Perk G, Mekler J, Ben ID, Bursztyn M. Non-dipping in diabetic patients: insights from the siesta. J Hum Hypertens 2002; 16: 435-438.
45. Wolf J, Hering D, Narkiewicz K. Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertens Res 2010; 33: 867-871.
46. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R, Bassetti C, Narkiewicz K, Mancia G, McNicholas WT. Position paper on the management of patients with obstructive sleep apnea and hypertension: Joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on Obstructive Sleep Apnea. J Hypertens 2012; 30: 633-646.
47. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130-135.
48. Mancia G, Omboni S, Parati G, Santucciu C, Trazzi S, Ulian L. Clinical value of ambulatory blood pressure monitoring. Am J Hypertens 1993; 6: 9S-13S.
49. Sommerfield AJ, Robinson L, Padfield PL, Strachan M. Clinical variables associated with non-dipping of nocturnal blood pressure in type 2 diabetes. Br J Diabetes Vasc Dis 2008; 8: 236-240.
50. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26: 177-189.
51. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894-900.
52. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Poulter NR, Sever PS. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-480.
53. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16: 1685-1691.
54. Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens Suppl 2005; 23: S19-S25.
55. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C, Corbellini C, Porteri E, Guelfi D, Rosei EA. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during anti-hypertensive treatment. J Hypertens 2001; 19: 703-711.
56. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995; 13: 1105-1112.
57. Staessen JA, Bieniaszewski L, Buntinx F, Celis H, O'Brien ET, van HR, Fagard R. The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial. Hypertension 1995; 26: 942-949.
58. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-558.
59. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens 2010; 28: 2177-2183.
60. Campo C, Saavedra J, Segura J, Roldan C, Ruilope LM, Parati G. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med 2005; 96: 365-371.
61. Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv Ther 2005; 22: 32-43.
62. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
63. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl 2), S13-S16.
64. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41-46.
65. Merck Canada Inc. Olmesartan medoxomil Product Monograph 2012.
66. Novartis Pharmaceuticals UK Ltd. Valsartan (Exforge) Summary of Product Characteristics 2011.
67. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132.
68. Redon J, Bilo G, Parati G. The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study. Blood Press (e-pub ahead of print 20 August 2013; doi: 10.3109/08037051.2013.789643).
69. Gosse P, Neutel JM, Schumacher H, Lacourciere Y, Williams B, Davidai G. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141-147.
70. Actavis UK Ltd. Amlodipine 5mg Summary of Product Characteristics 2012.
71. Wing L. Calcium channel antagonists. Aust Prescr 1997; 20: 5-8.
72. Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997; 10 (Suppl 3), 869-872.
73. Yamada S, Sugimoto N, Uchida S, Deguchi Y, Kimura R. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol 1994; 23: 466-472.
74. Casiglia E, Mazza A, Tikhonoff Vr, Basso G, Martini B, Scarpa R, Pessina A. Therapeutic profile of manidipine and lercanidipine in hypertensive patients. Adv Therapy 2004; 21: 357-369.
75. Taddei S, Omboni S, Ghiadoni L, Caiazza A, Fogari R, Innocenti P, Porcellati C, Giovannetti R, Corradi L, Mancia G, Salvetti A. Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients. J Cardiovasc Pharmacol 2003; 41: 579-585.
76. Antonicelli R, Omboni S, Giovanni DC, Ansuini R, Mori A, Gesuita R, Parati G, Paciaroni E. Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Drugs Aging 2002; 19: 541-551.
77. Reis RP, Basto MA, Martins LP, Cotta C, Palma MJ, Calaca J. P-47: Diltiazem 180 mg slow release capsules: evaluation of homogeneity of the antihypertensive effect with the smoothness index. Am J Hypertens 2002; 15: 50A.
78. Littlejohn TW III, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 207-213.
79. Littlejohn TW III, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4x4 factorial study. Postgrad Med 2009; 121: 5-14.
80. Parati G. Telmisartan Plus Amlodipine Combination Significantly Improves 24-h Blood Pressure Smoothness Index Compared with Monotherapies. The 4th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus 2011.
81. Takeda Global Research and Development Centre (Europe) Ltd. Azilsartan medoximil (Edarbi) Summary of Product Characteristics 2012.
82. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood Press Suppl 2001; 1: 27-32.
83. Takeda UK Ltd. Candesartan Summary of Product Characteristics 2011.
84. Malacco E, Piazza S, Meroni R, Milanesi A. Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study. Curr Ther Res 2000; 61: 789-797.
85. Gorbunov VM, Savina LV, Metelitsa VI, Deev AD. [Effects of the long-term treatment with losartan and captopril and of the abrupt cessation on circadian blood pressure profile]. Eksp Klin Farmakol 2001; 64: 45-50.
86. Hernandez RH, Armas-Hernandez MJ, Chourio JA, Armas-Padilla MC, Lopez L, Alvarez M, Pacheco B. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit 2001; 6: 47-57.
87. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-643.
88. Teva UK Ltd. Diltiazem SR Summary of Product Characteristics 2011.
89. Siddiqui MA, Plosker GL. Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension. Drugs 2004; 64: 1135-1148.
90. Stergiou GS, Efstathiou SP, Skeva II, Baibas NM, Roussias LG, Mountokalakis TD. Comparison of the smoothness index, the trough: peak ratio and the morning: evening ratio in assessing the features of the antihypertensive drug effect. J Hypertens 2003; 21: 913-920.
91. Actavis UK Ltd. Lisinopril Summary of Product Characteristics 2012.
92. Actavis UK Ltd. Ramipril Summary of Product Characteristics 2012.
93. Accord Healthcare Ltd. Captopril Summary of Product Characteristics 2012.
94. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, van Montfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. J Hypertens 2013; 31: 1731-1768.